Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
Read more -
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
Read more -
GSK presents college scholarships to Philadelphia students who have overcome adversity to pursue their dreams (1)
Media representatives are invited to GSK to attend a special event honoring the 2017 winners of the GSK Opportunity Scholarship program.
Read more -
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
GSK today announced results from a 10-year continuation study, which showed that Benlysta (belimumab) plus standard of care prolonged control of disease activity in patients wit...
Read more -
GSK presents college scholarships to Triangle Region, NC students who have overcome adversity to pursue their dreams (1)
Media representatives are invited to GSK to attend a special event honoring the 2017 winners of the GSK Opportunity Scholarship program.
Read more -
GSK and MMV announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention o...
Read more -
Four innovations to tackle under-five deaths win US$1 million Healthcare Innovation Award from GSK and Save the Children
Organisations in Pakistan, Colombia, India and Nigeria recognised for innovations helping the hardest-to-reach children Healthcare Innovation Award (HIA) is a major initiative ...
Read more -
ViiV Healthcare
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
Read more -
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
Read more -
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level
GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study in which first-in-class biologic Nucala (mepolizumab) consistently...
Read more -
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Read more -
GSK demonstrates leadership in respiratory medicine at ATS 2017 with over 50 abstracts from across comprehensive portfolio
GSK will present 59 abstracts at the American Thoracic Society (ATS) conference 19-24 May, Washington DC, US, from across its comprehensive respiratory portfolio.
Read more -
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced preliminary results of two pivotal phase III studies evaluating the efficacy and safety of mepolizumab, an IL-5 antagonist mon...
Read more -
GSK invests $139 million to expand production capacity for BENLYSTA (belimumab) in Rockville, MD
GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult pat...
Read more -
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care.
Read more -
GSK delivers another quarter of continued progress
GSK delivers another quarter of continued progress Q1 sales of £7.4 billion, +19% AER, + 5% CER Total EPS of 21.4p >100% AER, >100% CER; Adjusted EPS of 25.0p, +31% AER, +9% CER
Read more -
GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Follows regulatory submissions in US, EU and Canada
Read more -
Togo becomes first country in Africa to validate the elimination of lymphatic filariasis as a public health problem
LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted to humans through the bites of mosquitoes.
Read more -
GSK makes change to financial reporting framework
GSK keeps its financial reporting framework under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best p...
Read more -
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
